Bahrami Behdokht, Mohammadnia-Afrouzi Mousa, Bakhshaei Peyman, Yazdani Yaghoub, Ghalamfarsa Ghasem, Yousefi Mehdi, Sadreddini Sanam, Jadidi-Niaragh Farhad, Hojjat-Farsangi Mohammad
Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Tumour Biol. 2015 Aug;36(8):5727-42. doi: 10.1007/s13277-015-3706-6. Epub 2015 Jul 5.
The selective and efficient drug delivery to tumor cells can remarkably improve different cancer therapeutic approaches. There are several nanoparticles (NPs) which can act as a potent drug carrier for cancer therapy. However, the specific drug delivery to cancer cells is an important issue which should be considered before designing new NPs for in vivo application. It has been shown that cancer cells over-express folate receptor (FR) in order to improve their growth. As normal cells express a significantly lower levels of FR compared to tumor cells, it seems that folate molecules can be used as potent targeting moieties in different nanocarrier-based therapeutic approaches. Moreover, there is evidence which implies folate-conjugated NPs can selectively deliver anti-tumor drugs into cancer cells both in vitro and in vivo. In this review, we will discuss about the efficiency of different folate-conjugated NPs in cancer therapy.
将药物选择性且高效地递送至肿瘤细胞可显著改善不同的癌症治疗方法。有几种纳米颗粒(NPs)可作为癌症治疗的有效药物载体。然而,在设计用于体内应用的新型纳米颗粒之前,将药物特异性递送至癌细胞是一个应予以考虑的重要问题。研究表明,癌细胞过度表达叶酸受体(FR)以促进其生长。由于正常细胞表达的FR水平明显低于肿瘤细胞,因此叶酸分子似乎可作为不同基于纳米载体的治疗方法中的有效靶向部分。此外,有证据表明叶酸偶联的纳米颗粒在体外和体内均可将抗肿瘤药物选择性地递送至癌细胞。在本综述中,我们将讨论不同叶酸偶联纳米颗粒在癌症治疗中的效率。